68Ga-DOTATOC

DRUG4 trials

Sponsors

Universitair Medisch Centrum Groningen, Montefiore Medical Center, Jiangsu HengRui Medicine Co., Ltd., University Hospital, Grenoble

Conditions

Advanced Gastroenteropancreatic Neuroendocrine TumorBreast Cancer MetastaticNeuroendocrine Tumorsnasopharyngeal carcinoma

Phase 1

Towards improved therapy selection and targeted treatment for nasopharyngeal carcinoma. A proof-of-concept pilot study for somatostatin receptor 2 imaging with [68Ga]Ga-DOTA-TOC PET/CT: the NACASOR trial

RecruitingCTIS2025-520689-23-00

Universitair Medisch Centrum Groningennasopharyngeal carcinoma

Start: 2025-09-22Target: 10Updated: 2025-07-14

Phase 3

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

CompletedNCT03136328

Montefiore Medical CenterNeuroendocrine Tumors

Start: 2016-05-16End: 2017-03-31Updated: 2023-05-09

Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors

CompletedNCT06091748

Jiangsu HengRui Medicine Co., Ltd.Advanced Gastroenteropancreatic Neuroendocrine Tumor

Start: 2024-02-22End: 2025-11-27Updated: 2026-06-12

Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer

RecruitingNCT06611891

University Hospital, GrenobleBreast Cancer Metastatic

Start: 2025-01-06End: 2026-10-31Target: 25Updated: 2025-03-04